文献速递MDS 与骨髓增殖性肿瘤白血病

增殖与凋亡参数在髓系恶性肿瘤临床流式细胞术中的潜力

The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.
PubMed 文献 · Blood Adv · 2021-01-01

本文综述了增殖与凋亡标志物在髓系恶性肿瘤多参数流式细胞术中的应用潜力。尽管文献对骨髓增生异常综合征(MDS)、MDS/骨髓增殖性肿瘤和急性髓系白血病中这些过程的作用存在矛盾,但多参数流式细胞术的发展允许量化不同成熟阶段髓系细胞的增殖与凋亡指标,有望深化对疾病生物学和发病机制的理解。

要点

  • EuroFlow标准化为流式细胞术整合入白血病和淋巴瘤分类奠定基础。
  • 增殖与凋亡标志物在实体瘤和淋巴瘤诊断中已有价值,但在髓系恶性肿瘤中尚未纳入临床诊断。
  • 多参数流式细胞术可量化不同成熟阶段髓系细胞的增殖与凋亡指标。

核心结论

  • 增殖与凋亡标志物有潜力整合入髓系恶性肿瘤的现有多参数流式细胞术分析。
  • 多参数流式细胞术可量化不同成熟阶段髓系细胞的增殖与凋亡指标,促进对疾病生物学和发病机制的理解。

研究设计与样本

  • 本文为综述,检索并汇总了关于增殖与(抗)凋亡标志物在髓系恶性肿瘤诊断中应用的研究。

主要发现

  • 文献明确认识到增殖和凋亡机制在骨髓恶性肿瘤发病机制中的重要性。
  • 文献对MDS、MDS/MPN和AML中增殖与凋亡过程的作用存在矛盾。
  • 多项研究强调需分析造血骨髓细胞谱系亚群的增殖与凋亡率,认为这些结果对髓系恶性肿瘤患者有诊断和预后价值。

临床怎么用

  • 可利用多参数流式细胞术量化髓系细胞不同成熟阶段的增殖与(抗)凋亡指标,以辅助理解疾病生物学。

局限性

  • 文献对MDS、MDS/MPN和AML中增殖与凋亡的作用存在矛盾,且这些标志物尚未纳入临床诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standardization of the detection and quantification of leukocyte differentiation markers by the EuroFlow Consortium has led to a major step forward in the integration of flow cytometry into classification of leukemia and lymphoma. In our opinion, this now enables introduction of markers for more dynamic parameters, such as proliferative and (anti)apoptotic markers, which have proven their value in the field of histopathology in the diagnostic process of solid tumors and lymphoma. Although use of proliferative and (anti)apoptotic markers as objective parameters in the diagnostic process of myeloid malignancies was studied in the past decades, this did not result in the incorporation of these biomarkers into clinical diagnosis. This review addresses the potential of these markers for implementation in the current, state-of-the-art multiparameter analysis of myeloid malignancies. The reviewed studies clearly recognize the importance of proliferation and apoptotic mechanisms in the pathogenesis of bone marrow (BM) malignancies. The literature is, however, contradictory on the role of these processes in myelodysplastic syndrome (MDS), MDS/myeloproliferative neoplasms, and acute myeloid leukemia. Furthermore, several studies underline the need for the analysis of the proliferative and apoptotic rates in subsets of hematopoietic BM cell lineages and argue that these results can have diagnostic and prognostic value in patients with myeloid malignancies. Recent developments in multiparameter flow cytometry now allow quantification of proliferative and (anti)apoptotic indicators in myeloid cells during their different maturation stages of separate hematopoietic cell lineages. This will lead to a better understanding of the biology and pathogenesis of these malignancies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mestrum SGC, Hopman AHN, Ramaekers FCS, et al. The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies. Blood Adv. 2021. PMID: 33847740. doi:10.1182/bloodadvances.2020004094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。